Age dependence of tumor genetics in unfavorable neuroblastoma: arrayCGH profiles of 34 consecutive cases, using a Swedish 25-year neuroblastoma cohort for validation by unknown
Cetinkaya et al. BMC Cancer 2013, 13:231
http://www.biomedcentral.com/1471-2407/13/231RESEARCH ARTICLE Open AccessAge dependence of tumor genetics in
unfavorable neuroblastoma: arrayCGH profiles of
34 consecutive cases, using a Swedish 25-year
neuroblastoma cohort for validation
Cihan Cetinkaya1,2, Tommy Martinsson3, Johanna Sandgren1,4, Catarina Träger5, Per Kogner5, Jan Dumanski1,
Teresita Díaz de Ståhl1,4† and Fredrik Hedborg1,6*†Abstract
Background: Aggressive neuroblastoma remains a significant cause of childhood cancer death despite current
intensive multimodal treatment protocols. The purpose of the present work was to characterize the genetic and
clinical diversity of such tumors by high resolution arrayCGH profiling.
Methods: Based on a 32K BAC whole-genome tiling path array and using 50-250K Affymetrix SNP array platforms
for verification, DNA copy number profiles were generated for 34 consecutive high-risk or lethal outcome
neuroblastomas. In addition, age and MYCN amplification (MNA) status were retrieved for 112 unfavorable
neuroblastomas of the Swedish Childhood Cancer Registry, representing a 25-year neuroblastoma cohort of
Sweden, here used for validation of the findings. Statistical tests used were: Fisher’s exact test, Bayes moderated
t-test, independent samples t-test, and correlation analysis.
Results: MNA or segmental 11q loss (11q-) was found in 28/34 tumors. With two exceptions, these aberrations
were mutually exclusive. Children with MNA tumors were diagnosed at significantly younger ages than those with
11q- tumors (mean: 27.4 vs. 69.5 months; p=0.008; n=14/12), and MNA tumors had significantly fewer segmental
chromosomal aberrations (mean: 5.5 vs. 12.0; p<0.001). Furthermore, in the 11q- tumor group a positive correlation
was seen between the number of segmental aberrations and the age at diagnosis (Pearson Correlation 0.606;
p=0.037). Among nonMNA/non11q- tumors (n=6), one tumor displayed amplicons on 11q and 12q and three
others bore evidence of progression from low-risk tumors due to retrospective evidence of disease six years before
diagnosis, or due to tumor profiles with high proportions of numerical chromosomal aberrations. An early age at
diagnosis of MNA neuroblastomas was verified by registry data, with an average of 29.2 months for 43 cases that
were not included in the present study.
Conclusion: MNA and segmental 11q loss define two major genetic variants of unfavorable neuroblastoma with
apparent differences in their pace of tumor evolution and in genomic integrity. Other possible, but less common,
routes in the development of aggressive tumors are progression of low-risk infant-type lesions, and gene
amplifications other than MYCN. Knowledge on such nosological diversity of aggressive neuroblastoma might
influence future strategies for therapy.
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Neuroblastoma is a childhood malignancy that arises
from embryonic cells of the sympathetic ganglia or the
adrenal medulla [1]. It is mainly a disease of infants and
toddlers; more than half of patients with neuroblastoma
are diagnosed before two years of age and ~90 percent
before age six [2,3]. This age dependence of the inci-
dence of neuroblastoma may be a consequence of devel-
opmentally determined disappearance of the pool of
immature cells from which neuroblastomas are thought
to derive. The disease is clinically diverse, and ranges
from cases with a very dismal prognosis, despite modern
intensive multimodal therapy, to those with an excellent
chance of survival [2]. This variation in clinical behavior
is also highly age dependent: children who are diagnosed
after two years of age suffer predominantly from aggres-
sive forms. Neuroblastomas that are diagnosed during
adolescence and young adulthood are rare, but they are
of particular concern because they almost invariably pro-
gress, although with an indolent course [4,5]. In sharp
contrast, tumors that are diagnosed before 18 months of
age are generally associated with a favorable prognosis.
Such tumors are usually less advanced, have a propensity
for spontaneous involution or maturation, and respond
well to mild chemotherapy [2].
These clinical differences correspond to clear differ-
ences in tumor genetics [2]. As a general rule, prognos-
tically favorable tumors display numerical imbalances of
entire chromosomes and have near-triploid DNA con-
tent, whereas higher-risk tumors present with segmental
chromosomal aberrations (SCAs) and are often pseudo-
diploid. MYCN gene amplification (MNA) was one of the
first genetic markers for highly aggressive neuroblastoma
to be established [6], and remains a powerful prognostic
indicator [7]. More recently, an independent prognostic
value of a segmental deletion of 11q has also been recog-
nized [7-9]. Both these aberrations are incorporated in the
present International Neuroblastoma Risk Group (INRG)
classification system for treatment stratification [10]. Sev-
eral arrayCGH studies in the recent years support the
MNA/segmental 11q loss dichotomy of high-risk neuro-
blastoma and indicate that any type of segmental numer-
ical chromosomal aberration is a negative prognostic sign
[11-13]. However, the representativeness of the studied
tumor materials may be questioned because the tumors
were from multiple sources and, hence, selection bias
may have occurred. Therefore, the present study aims at
characterizing the heterogeneity of genetic aberrations in
aggressive neuroblastoma by exploiting a consecutive,
population-based series of tumors, the representativeness
of which was tested against data in the Swedish Childhood
Cancer Registry. The most striking observations were re-
lated to age at tumor presentation: MNA tumors were as-
sociated with a particularly early age at diagnosis and lownumbers of other chromosomal aberrations suggesting
a rapid tumor evolution with few genetic hits involved,
whereas 11q deleted tumors were diagnosed at older ages
and showed significantly more SCAs, the numbers of
which were positively correlated with the age at diagnosis,
suggesting a chromosomal instability phenotype with a
more stepwise tumor evolution. Other tumors seemed to
be the result of late progression of low-risk neuroblastoma
or of gene amplifications other than MYCN. This clin-
icogenetic diversity of unfavorable neuroblastoma is likely
to reflect differences in tumor evolution and growth,
which may have therapeutic implications.Methods
Study design
In order to obtain a representative view at high reso-
lution of DNA copy number aberrations in aggressive
forms of neuroblastoma a 32K BACwhole-genome tiling
path arrayCGH platform was applied to a consecutive,
population-based tumor material (described below). The
representativeness of the tumor collection was analyzed
by comparing the patients’ ages at diagnosis and propor-
tions of tumors in relation to the presence or absence
of MNA with the corresponding data of neuroblastomas
registered in the Swedish Childhood Cancer Registry dur-
ing a 25-year period. For verification of the BACarray-
based profiles high-resolution SNP array analyses were
performed. Based on publically available gene expression
data from neuroblastoma, expression profiles were com-
pared between tumor groups for certain chromosomal re-
gions of interest.Patient material
Fresh frozen specimens of neuroblastoma were collected
consecutively during the period 1986–1994 at all Swedish
centers at which pediatric tumor surgery is performed
[14]. Samples collected between 1995 and 2010 at Uppsala
University Hospital, which treats approximately 20 per-
cent of Swedish patients with neuroblastoma, were also
included. The inclusion criteria were: high-risk neuro-
blastoma, as defined by the INRG classification system
[10], progression to disseminated fatal disease, and stage
L2 tumors in children >12 years of age at diagnosis (one
case). The INRG high-risk criteria applied here were:
Stage M tumors in children >18 months of age at diagno-
sis and all tumors with MNA. Stage MS tumors were
excluded. The individual clinical data of all 34 cases in-
cluded in the study are shown in Table 1.
To ensure that the tumor specimens represented viable
tumor tissue their quality was assessed from hematoxylin/
eosin stained cryosections, requiring a tumor cell content
of at least 60–70%. Ethical approval was obtained from
the Regional Ethical Review Board in Uppsala (approval
Table 1 Clinical data and main genetic findings of 34 unfavorable neuroblastomas
ID Age Sex Stage Outcome Followup Survival median Site WCA WCA SCA SCA MNA 11q- Array platform
(mo) (INRGSS) (mo) (mo) (nr) (average) (nr) (average)
52* 4 m M DOD 10 adr 0 6 + 32K
55 8 f M DOD 16 adr 0 6 + 32K, Affymetrix
106* 10 f M NED 265 adr 0 12 + 32K
123* 11 f M DOD 3 adr 0 6 + 32K, Affymetrix
241* 11 m M DOD 8 adr 1 3 + 32K, Affymetrix
244 14 f M DOD 22 adr 8 2 + Affymetrix
212 15 m M DOD 5 adr 0 2 + 32K, Affymetrix
240* 21 f M NED 43 adr 0 3 + 32K, Affymetrix
135* 22 m L2 DOD 3 adr 0 3 + 32K, Affymetrix
95* 26 f M DOD 15 adr 0 8 + 32K
238 30 f M DOD 24 adr 0 6 + Affymetrix
207 37 f M DOD 7 adr 2 5 + 32K, Affymetrix
217 37 m M DOD 36 adr 0 8 + 32K
126 138 m M DOD 9 adr 0 7 + 32K, Affymetrix
MNAnot11q- 9.5 0.8 5.5
68 41 m M DOD 12 adr 9 7 + + 32K, Affymetrix
136* 48 f L2 DOD 12 adr 1 8 + + 32K
MNA & 11q- 12.0 5.0 7.5
243 32 f M DOD 28 adr 2 10 + Affymetrix
149 34 m M DOD 16 adr 0 12 + 32K, Affymetrix
112 40 m M DOD 18 adr 1 3 + 32K, Affymetrix
111* 42 f M NED 262 adr 0 7 + 32K
155 52 f M DOD 19 adr 3 13 + 32K, Affymetrix
32* 57 m M DOD 12 adr 2 15 + 32K, Affymetrix
110 60 m M DOD 12 adr 1 14 + 32K, Affymetrix
69* 60 m L2 DOD 17 th 1 14 + 32K, Affymetrix
41* 77 f M DOD 8 th 2 15 + 32K, Affymetrix
49 82 m M DOD 14 adr 3 10 + 32K, Affymetrix
209 129 m M DOD 35 adr 2 10 + 32K, Affymetrix


















Table 1 Clinical data and main genetic findings of 34 unfavorable neuroblastomas (Continued)
11q-notMNA 16.5 1.5 12.0
107* 23 m M DOD 10 adr 1 2 32K, Affymetriix
131 37 f L2 DOD 21 adr 13 1 32K, Affymetriix
130 46 m M DOD 57 adr 0 3 32K, Affymetriix
208 59 m L2 DOD 25 renal 4 3 32K
242* 90 f M SD 37 th 12 5 32K, Affymetriix
226* 91 m M SD 61 th 2 12 32K, Affymetriix
Not MNA not 11q- 23.0 5.3 4.3
Cases are sorted on the basis of genetic category, as determined by the presence of MNA and segmental loss of 11q. Within each tumor category, cases are sorted according to age at diagnosis. Abbreviations: DOD:
dead of disease; NED: no evidence of disease; SD: stable disease; WCA: whole-chromosome copy number aberration; SCA: segmental chromosomal copy number aberration; adr: adrenal; th: thoracic. Tumors marked
with asterisk (*) with IDs: 52, 106, 123, 241, 240, 135, 95, 136, 111, 32, 69, 41, 107, 242, and 226 are reported also by Carén et al. [15] with the respective codes: 7, 14, 8, 2, 4, 13, 12, 37, 40, 42, 44, 39, 66, 73, and 63, as
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from the parents.
There is an overlap between tumors included in this
work and those of a similar Swedish report [15]. How-
ever, our study is based on another collection of biopsies
from a partially different set of tumors. The previously
reported Affymetrix SNParray data [15] was used for verifi-
cation of our BACarray results on tumors common to both
studies (n=15) and for verification of our data on presently
unique tumors (n=19) new original SNParray data was pro-
duced. Tumors in common with the aforementioned study
are indicated in Table 1 and information on their previous
codes [15; Table S1] is given in the table legend.
Array-based comparative genomic hybridization
The 32K BAC array was established as reported previ-
ously [16]. High-quality DNA was obtained by standard
methods [17]. DNA labeling, hybridization, washing, scan-
ning of arrays, and data processing were performed as
described earlier [16,18-20]. Experiments using 50K and
250K Affymetrix arrays were performed in accordance
with the manufacturer’s protocol (Affymetrix, Inc., Santa
Clara, CA), and as described earlier [21].
Microarray expression data
Publically available gene expression data from high-risk
metastatic neuroblastomas, series GSE13136 [22], plat-
form Affymetrix Human Genome U133 Plus 2.0, which
were selected by the presence of MNA (GSM328993,
GSM328996, GSM329000, GSM329006, GSM329007, GS
M329008, GSM329011, GSM329012, GSM329013, GSM
329015) or segmental 11q loss (GSM328992, GSM328995,
GSM328997, GSM328999, GSM329002, GSM329010, GS
M329014, GSM329017) were downloaded from Gene
Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/)
and normalized in Expression Console v1.1 (3' Expression
Arrays-RMA, Affymetrix).
The Swedish childhood cancer database
Clinical data and the MYCN copy number status for
neuroblastomas diagnosed in Sweden during the 25-year
period of 1984–2008 were obtained from the Swedish
Childhood Cancer Registry. The clinical criteria for in-
clusion were the same as for the array study. The limit
for MNA was set at >4 copies of MYCN per haploid
genome, as determined by FISH and/or SNParray.
Statistical analysis
To analyze differences in DNA copy number among the
tumor groups, Fisher’s exact test was used within the Nexus
Copy Number 5.0 analysis program (BioDiscovery, Inc.,
El Segundo, CA, USA). To search for genes that were dif-
ferentially expressed among the tumor groups, an empiri-
cal Bayes moderated t-test was applied using the ‘limma’package [23] and p-values were adjusted in accordance with
the method of Benjamini and Hochberg [24]. Clinical data
were processed using PASW Statistics 18.0 software (SPSS;
Chicago, IL, USA). Mean differences in age were examined
with the t-test for independent samples. Co-variations were
analyzed by correlation analysis, and the results were
expressed as Pearson correlation coefficients.
Results
Identification of two major unfavorable neuroblastoma
groups with different genomic signatures
To visualize the results from the complete set of tumors,
the percentages of tumors with copy number change
were calculated and plotted relative to the position along
the chromosomes (Figure 1A). All individual profiles are
also illustrated (Additional file 1: Figure S1). Partial or
complete gain of one or two copies of the 17q arm was
the most common aberration (88% of the tumors), fol-
lowed by loss of 1p segments (56%), MNA (47%), and
loss of 11q (47%; 14 tumors with segmental loss and 2
with loss of one entire chromosome 11) (Figure 1A and
Additional file 1: Figure S1). Subsequently, we examined
the frequencies of copy number changes in tumor sub-
groups that were defined on the basis of the absence or
presence of MNA and segmental 11q loss (11q-); hence,
the tumors were separated into four subgroups: MNAnot11q-
(n=14), 11q-notMNA (n=12), MNA and 11q- (n=2), and
neither MNA nor 11q- (n=6). The results are shown in
Figure 1B-D and Additional file 1: Figure S1. Selected pro-
files from each group are shown in Figure 2. Analysis using
Fisher’s exact test of differences between the MNAnot11q-
and 11q-notMNA groups (which contained most of the sam-
ples, 26/34; 76%) revealed that loci on 1p, 2p, 3p, 5q, 7, 11,
12, 18p, and 20q were differentially altered between the two
sets of tumors (Figure 1E). These groups also differed in
terms of the number of SCAs (mean 5.5 and 12.0, respec-
tively; Table 1, p<0.001, Wilcoxon’s test), and with regard to
an absence of numerical whole chromosomal aberrations,
which was the case in 11/14 MNAnot11q- tumors, but
in only 2/12 11q-notMNA tumors (Table 1 and Additional
file 1: Figure S1). Finally, tumors that showed neither MNA
nor 11q- were more heterogeneous in terms of both seg-
mental and whole chromosomal aberrations; two tumors
showed aberrations in chromosome number for the ma-
jority of chromosomes (ID 131 and ID 242; Table 1 and
Additional file 1: Figure S1).
Age dependence of genetic subgroups
As shown in Table 1 and in Figure 3, MNA tumors were
diagnosed early in life. In fact, 11 out of the 12 children
who were youngest at diagnosis suffered from MNA tu-
mors. If an outlier amongst the MNA group in terms of
genetic profile and age (ID126; Table 1 and Additional
file 1: Figure S1) is disregarded, only two 11q-notMNA
Figure 1 Genetic findings in unfavorable neuroblastoma. The frequency of copy number changes was calculated for all measurement points
in the arrays and plotted relative to the position along the chromosome for: (A): all tumors, (B): MNAnot11q- tumors, (C): 11q-notMNA tumors,
(D): neither MNA nor 11q loss tumors. The number of analyzed tumors is indicated (n). Green bars above the horizontal line indicate the
percentage of tumors with copy gains and red bars below the horizontal line indicate the percentage of tumors with copy losses. Data for the
X chromosome were normalized to female reference DNA and the respective proportion of boys in panels A-D were: 56%, 43%, 67%, and 67%,
respectively (E): To search for copy number alterations that differ between the11q-notMNA and MNAnot11q- groups, the frequency percentage
difference between the two groups are plotted: Copy number gain difference (green graph): Values above baseline represent regions in which
gains are more numerous among 11q-not MNA tumors, and vice versa for values below baseline. Deletion difference (red graph): Values above
baseline represent regions in which losses are more common among MNAnot11q- tumors, and vice versa for values below baseline. The regions
significantly differentially altered between the groups, identified by using Fisher's exact test within Nexus copy-number software, (p<0.05 and
threshold difference in frequency >25%), are shown below the graph, as indicated by a black arrow.
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that of the remaining MNAnot11q- tumors (Table 1 and
Figure 3). Statistically, the ages at diagnosis of children
with MNAnot11q- tumors differed highly significantly from
those of children with 11q-notMNA tumors (mean age: 27.4
vs. 69.5 months, respectively; p=0.008; median age: 18 vs.
58.5 months, respectively; n=14 vs. 12).
To test the validity of these findings in a larger sample,
we utilized the Swedish Childhood Cancer Registry,
which contained clinical information and data on the
copy number of MYCN in tumors for 240 cases of
neuroblastoma that were diagnosed during almost the
same time period as the cases in the present study.
Among these, 112 were unfavorable cases (100 high risk
and 12 intermediate risk who suffered lethal tumor pro-
gression). Of the tumors included in the current study,25 were represented among these 112 cases in the regis-
try, and 11 of the 25 were cases with MNA. Given that
11q status is not registered consistently in the database,
we compared the age at diagnosis of children with MNA
tumors to those with non-MNA tumors. This analysis
revealed highly significant differences both for the pre-
sent study (MNA vs. non-MNA: mean: 29.5 vs. 65.6
months; p=0.005; median age: 21 vs. 58 months; n=16
vs. 18) and for cases of unfavorable neuroblastoma in
the registry that were not included in the present study
(MNA vs. non-MNA: mean age: 29.2 vs. 49.1 months;
p=0.001; median age: 24 vs. 43.5 months; n=43 vs. 44).
To determine whether the MNA cases included in our
study might be biased towards a younger age range, we
compared their ages at diagnosis to those of the other
MNA cases in the registry and found no statistical
Figure 2 Examples of individual neuroblastoma profiles within genetic subgroups. (A) MNAnot11q-; (B) 11q-notMNA; (C) combined MNA and
segmental 11q loss; (D) neither MNA nor segmental 11q loss; (E) shows an expanded segment of chromosome 12 in panel (D). Amplified genes
of particular oncogenic interest are indicated. Each individual clone was assigned a copy number class as follows: i) balanced: two alleles (blue
dots); ii) gained: presence of three (red) or more (pink dots) alleles; or iii) deleted: hemizygous deletions (green dots). No homozygous deletions
were found in these tumors. Black arrows indicate MNA amplification, 11q loss or other amplifications.
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Figure 3 Age at diagnosis in unfavorable neuroblastoma
(n=34). Each tumor in the present study is plotted on a time axis
according to age at diagnosis and genetic subgroup. Color symbols
indicate the likely site of origin.
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months; p=0.968; n=16 vs. 43). There was also no statisti-
cally significant difference in the distribution of ages at
diagnosis for non-MNA tumors (mean: 65.6 vs. 49.1
months; median: 58 vs. 43.5 months; p=0.098; n=18 vs. 44).Figure 4 MYCN amplification status and age at diagnosis of Swedish
representing the period 1986–2010, have been merged with all other case
Cancer Registry during the period 1984–2008. Data is presented in 6-mont
MYCN amplification, INRGSS Stage M and >18 months of age at diagnosis,When the findings were merged, we were able to con-
clude that, among Swedish children who were diagnosed
with unfavorable neuroblastoma during this time period,
MNA tumors were almost four-fold more common than
non-MNA tumors when diagnosis was made before two
years of age (31 vs. 8), whereas this relationship was re-
versed in children who were diagnosed after 3.5 years of
age (10 vs. 35; Figure 4).
In view of the high number of SCAs that were found in
tumors with segmental 11q deletion, we investigated the
possibility of an age-dependence for the number of SCAs
within this tumor subgroup and found a positive corre-
lation with age at diagnosis (Pearson correlation 0.606;
p=0.037). When merging the four genetic groups the age
dependence of SCA numbers was even more evident with
a p-value of 0.001 (Pearson correlation 0.547; Figure 5).High copy number amplicons
In total, 17 tumors displayed amplified regions. The number
of these amplified regions per tumor varied from one to
seven, and their sizes ranged from 0.15 to 6.8 Mb. Of the
16 tumors with MNA, either the MYCN-containingpatients with unfavorable neuroblastoma (n=121). Present cases,
s of unfavorable neuroblastoma found in the Swedish Childhood
h age intervals. Unfavorable criteria were: lethal tumor progression,
and INRGSS Stage L2 >12 years of age at diagnosis.
Figure 5 Age dependence of segmental chromosomal
aberrations in unfavorable neuroblastoma (n=34). Data are
separated by genetic subtype, as indicated. X-axis: age at diagnosis
(years). Y-axis: number of segmental chromosomal aberrations (SCA;
amplicons not included).
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panied by multiple amplified loci within 2p, and in one case
by two amplified loci on chromosome 3q. The regions of
amplification, their frequencies, and the genes encompassed
are listed in Table 2. In one tumor with MNA and its asso-
ciated cell line [15], a few novel amplicons were found,
which encompassed genes such as GDF7, FSHR, PRKCE,
and TMEM18 (Additional file 2: Figure S2). Overall, 20% of
the amplified loci did not encompass any gene (Table 2).
One unusual case (ID 208) displayed multiple amplicons
but not MNA. Genes of particular oncogenic interest within
these loci were CCND1, FGF4, FGF19, IGHMBP2, MYEOV,
and ORAOV1 on 11q13.2-q13.3 and CDK4, MDM2, and
KSR2 on 12q13.3-q15 (Figure 2D-E and Table 2).
Differentially expressed genes within aberrant regions of
MNA and 11q-deleted tumors
Given that MNA and 11q- neuroblastomas present with
divergent genomic signatures, we sought differences in
gene expression profiles within the regions that differed
most consistently between these two groups (1p, 2p, and
chromosomes 7 and 11). For this purpose, we compared
publicly available gene expression data for high-risk neu-
roblastomas with recorded MNA and 11q status (see
Methods). Among the MNA tumors (n=10), five tumor
suppressor genes (among other genes) were underex-
pressed within the distal 1p: CAMTA1, KIF1B, PRDM2,
FABP3, and CDKN2C; whereas MYCNOS and MYCN
were the two top differentially upregulated genes on 2p.
Several constituents of the extracellular matrix or mem-
brane proteins involved in cell adhesion, motility or pro-
liferation that map to chromosome 7, namely PTN,
CNTNAP2, ELN, HSPB1, SEMA3E, and COL1A2, wereupregulated in the 11q-deleted group (n=8). In the same
group of tumors, CD44 was the top upregulated gene on
11p. Interestingly, on 11q, several tumor suppressor genes
and genes encoding DNA-binding proteins involved in
DNA repair and negative regulation of transcription were
downregulated in the 11q-deleted tumors: C11orf30, RSF1,
CREBZF, FAT3, MRE11A, ATM, CADM1, MLL, H2AFX,
TBRG1, and CHK1.
Discussion
In this report, we describe the DNA copy number pro-
files of a consecutive series of neuroblastomas that were
selected on the basis of unfavorable characteristics. The
findings revealed considerable genetic heterogeneity within
this clinically troublesome group, which was particularly
evident when comparing tumors with MNA to those with
segmental 11q deletions. With few exceptions, MNA and
segmental 11q loss were mutually exclusive and defined
two genetic subgroups of equal size that comprised more
than three-quarters of the total samples. Such genetic
dichotomy of advanced neuroblastoma has been well de-
scribed previously [2,7,8,11,15] and both MNA and seg-
mental 11q loss are included in the current INRG
algorithm for pretreatment stratification of risk [10]. Less
predictably, we also observed a clear clinical difference be-
tween these two genetic subgroups in relation to age:
MNA tumors affected the youngest children of the series.
It is surprising that this age dependence with respect to
the tumor genetics of neuroblastoma has not received
much scientific attention previously, although mentioned
in several previous studies [9,11,15,25]. In view of the rela-
tively moderate size of the present tumor series, it was
important that we were able to confirm a generally low
age at diagnosis for children with MNA tumors using
independent data from the Swedish Childhood Cancer
Registry; these data argued clearly against a bias in the
present material. We conclude from the present findings
that unfavorable neuroblastomas are predominantly of the
MNA type when diagnosed under the age of 2 years,
whereas tumors with loss of 11q and other genetic variants
predominate after 3.5 years of age.
As the Swedish Childhood Cancer Registry, due to
lack of records, could not be used to verify the older age
at diagnosis for children with 11q-deleted tumors we
searched the literature for this information: Spitz et al.
[9] reported on segmental 11q deletions from a cohort
of 611 neuroblastomas, found in 159 tumors. The me-
dian age at diagnosis of these 11q-deleted tumors was
3–5 years, constituting 59 percent of the tumors of this
age range. Michels et al. [11] reported 48 and 28 months as
median ages at diagnosis for ten 11q-deleted and 22 MNA
tumors, respectively. In a meta study by Vandesompele
et al. [25] poor risk neuroblastomas were separated into
two genetic “clusters”: The median age of 45 children
Table 2 Regions of amplification in unfavorable neuroblastoma (n=17)
Chr Region (Mb) Cyto-band Length(Mb) Genes Gene Symbols Group No of tumors
chr:2:0.366-0.793 p25.3 0.427 1 TMEM18 NMA 1
chr:2:2.304-6.219 p25.3-p25.2 3.915 12 ADI1, ALLC, COLEC11, LOC150622, LOC400940,
LOC730811, MYT1L, RNASEH1, RPS7,
SOX11, TSSC1, TTC15
NMA 1
chr:2:3.605-4.280 p25.3 0.675 3 ALLC, COLEC11, RPS7 NMA 1
chr:2:5.708-7.439 p25.2-p25.1 1.731 6 CMPK2, LOC150622, LOC400940, RNF144A,
RSAD2, SOX11
NMA 1
chr:2:6.372-6.855 p25.2 0.483 0 NMA 1
chr:2:10.413-11.244 p25.1 0.831 10 ATP6V1C2, C2orf50, HPCAL1, KCNF1, NOL10,
ODC1, PDIA6, PQLC3, ROCK2, SNORA80B
NMA 2
chr:2:11.622-11.878 p25.1 0.256 3 GREB1, LPIN1, NTSR2 NMA 1
chr:2:13.097-13.580 p24.3 0.483 0 NMA 1
chr:2:14.219-14.292 p24.3 0.073 0 NMA 2
chr:2:15.895-16.095 p24.3 0.200 2 MYCN, MYCNOS NMA 16
chr:2:16.675-16.705 p24.3 0.030 1 FAM49A NMA 6
chr:2:16.846-17.106 p24.3-p24.2 0.260 0 NMA 6
chr:2:18.197-18.423 p24.2 0.227 0 NMA 3
chr:2:20.546-21.012 p24.1 0.466 3 C2orf43, GDF7, HS1BP3 NMA 1
chr:2:22.493-25.674 p24.1-p23.3 3.181 21 ADCY3, ATAD2B, C2orf44, C2orf79, C2orf84,
CENPO, DNAJC27, DNMT3A, DTNB, EFR3B,
FKBP1B, ITSN2, KLHL29, LOC375190, MFSD2B,
NCOA1, PFN4, POMC, SF3B14, TP53I3, UBXN2A
NMA 1
chr:2:26.853-27.169 p23.3 0.316 9 AGBL5, C2orf18, CENPA, DPYSL5, EMILIN1, KHK,
LOC100128731, MAPRE3, TMEM214
NMA 2
chr:2:28.022-28.430 p23.2 0.408 1 BRE NMA 2
chr:2:29.071-30.833 p23.2-p23.1 1.762 8 ALK, C2orf71, CAPN13, CLIP4, FAM179A, LBH,
LCLAT1, YPEL5
NMA 2
chr:2:38.841-39.010 p22.1 0.168 4 DHX57, GEMIN6, LOC100271715, MORN2 NMA 1
chr:2:45.742-46.467 p21 0.725 2 EPAS1, PRKCE NMA 1
chr:2:47.379-47.698 p21-p16.3 0.319 3 EPCAM, KCNK12, MSH2 NMA 1
chr:2:48.848-49.512 p16.3 0.664 1 FSHR NMA 1
chr:3:170.768-172.093 q26.2 1.325 18 ARPM1, CLDN11, EIF5A2, GPR160, LOC100128164,
LRRC31, LRRC34, LRRIQ4, MECOM, MYNN, PHC3,
PRKCI, RPL22L1, SAMD7, SEC62, SKIL, SLC7A14, TERC
NMA 1
chr:3:173.047-173.459 q26.31 0.411 2 FNDC3B, TMEM212 NMA 1
chr:11:68.463-69.308 q13.2-q13.3 0.845 9 CCND1, FGF19, FGF4, IGHMBP2, MRGPRD,
MRGPRF, MYEOV, ORAOV1, TPCN2
Not NMA, not 11q- 1
chr:12:56.182-57.066 q13.3-q14.1 0.884 23 AGAP2, AVIL, B4GALNT1, CDK4, CTDSP2,
CYP27B1, DCTN2, DDIT3, DTX3, FAM119B,
GEFT, KIF5A, LOC100130776, MARCH9, MARS,
MBD6, METTL1, OS9, PIP4K2C, SLC26A10,
TSFM, TSPAN31, XRCC6BP1
Not NMA, not 11q- 1
chr:12:67.060-68.692 q15 1.632 13 BEST3, CCT2, CPM, CPSF6, FRS2, LRRC10, LYZ,
MDM2, NUP107, RAB3IP, RAP1B, SLC35E3, YEATS4
Not NMA, not 11q- 1
chr:12:71.578-73.413 q21.1 1.835 1 LOC552889 Not NMA, not 11q- 1
chr:12:83.287-83.563 q21.31 0.276 0 Not NMA, not 11q- 1
chr:12:116.476-116.802 q24.22-q24.23 0.326 1 KSR2 Not NMA, not 11q- 1
Regions that involved at least two neighboring clones, with copy number count >3 and normalized fluorescence ratio >2 are shown. For amplicons with regions
shared between tumors, the minimal overlapping region is shown. Genes of particular oncogenic interest in neuroblastoma are indicated in bold.
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http://www.biomedcentral.com/1471-2407/13/231belonging to the 11q deletion “cluster” was 41 months, al-
though notably only 30 of the tumors were actually 11q de-
leted. The corresponding figures for 74 children belonging
to the MNA “cluster” was 26.9 months median age with
actual MNA seen in 51 tumors. Finally, Carén et al. [15]
reported a median age of 42 months for 21 children with
11q-deleted tumors (four of which were common with our
study) compared to 21 months for 37 children with MNA
tumors (seven in common with our study). Together, these
data consistently support an age difference between the
two groups, although a certain bias towards older ages for
11q-deleted tumors in the present study is observed (58.5
months median age).
Another difference that was observed between MNA and
11q-deleted tumors was the higher number of SCAs in the
later group of tumors and a dependence of their prevalence
on age, both of which imply a chromosomal instability
phenotype, as suggested previously by Carén et al. [15]. Fu-
ture analyses using larger sample sizes, including multiple
tumor specimens (synchronous and metachronous), might
be helpful in confirming such chromosomal instability.
Also, deep sequencing might shed additional light on differ-
ences in genomic integrity at the DNA level among subsets
of neuroblastoma. A recent report [26], based on whole-
genome sequencing of 87 neuroblastomas of all stages,
showed that the frequency of somatic amino-acid-changing
mutations strongly correlated to tumor stage, survival, and
age at diagnosis. However, no difference in frequency of
such mutations was detected when comparing MNA tu-
mors to high-stage non-MNA tumors. Hence, this afor-
mentioned study reported a general age dependence of
amino-acid-changing mutations in neuroblastoma, albeit
the specific issue of DNA instability in tumors with deleted
11q, as compared to MNA tumors, was not addressed.
On the basis of the profile subtypes that were observed
in the presently relatively limited series of tumors, and in
view of previous data by others, we speculate on the exis-
tence of four genetic routes for the genesis of aggressive
neuroblastoma:
The MNA route
MNA neuroblastomas seem to fit into a model of rapid
tumor evolution that involves only a few genetic events,
which transform the progenitor cells into highly prolifera-
tive and primary metastatic tumor cells in a straightforward
fashion. The likelihood of such few events to take place
would, logically, be more proportional to the pool of cells
of origin than for tumors requiring a larger sequence of
genetic hits (e.g. 11q deleted tumors), hence explaining the
early in life appearance of MNA tumors.
The 11q route
It appears that the pathogenesis of tumors with segmen-
tal 11q loss accords with the traditional genetic modelfor adult cancer, which predicts a micro-evolutionary
process of cancer development, with successive genetic
hits affecting key cellular functions [27]. Acquisition of
chromosomal instability might be fundamental in this
process. Our analysis of differential gene expression in
11q-deleted tumors vs. MNA neuroblastomas pinpointed
some candidate tumor suppressor/DNA repair genes
within the region of 11q that is deleted, such as ATM,
MLL, H2AFX, and CHK1. Recently, the importance of
aberrant gene expression within this region was under-
scored by the finding that decreased expression of genes
within the region of interest at 11q was observed only in
those 11q-deleted tumors with an aggressive clinical
phenotype [28]. It is noteworthy, in this context, that a
subgroup of 11q-deleted tumors with more favorable clin-
ical characteristics has been described [28,29]. Apart from
not showing a disproportionate downregulation of the ex-
pression of genes of the deleted region, such tumors were
also reported to differ from unfavourable 11q-deleted tu-
mors regarding microRNA expression profiles [29] and by
having less SCAs [28]. It is therefore possible that the here
suggested 11q route is not an important element in the
pathogenesis of less aggressive tumors with 11q deletions.
Evidently, our statistics on the present 11q-notMNA tumors
represents the unfavorable type of 11q-deleted neuroblas-
toma since there was only one survivor in this group. It is
noticeable in this context that our inclusion criteria would
discriminate against tumors of the more favorable subtype.
The tumor progression route
A third possibility in the evolution of aggressive neuro-
blastoma is progression from lower-risk tumors [13]. Al-
though progression from a low-risk lesion to an aggressive
tumor is considered in general to be a rare event, we think
that three of the nonMNA/non11q deleted tumors in the
present study might have evolved in this way. Two tumors
showed genetic similarity to low-risk tumors in that they
showed whole chromosome aberrations for more than half
of the chromosomes and only few segmental gains
or losses. It appears particularly likely that a third tumor
(ID 226) was derived from a lower-risk tumor: on diagno-
sis at 7.5 years of age, it was revealed that a chest X-ray
taken 6 years earlier already then showed the primary
tumor. Genetically, the tumor had much in common with
11q deleted tumors, but 11q was intact.
Alternative amplicon driven routes
An unusual genetic variant of the present study was a
tumor with multiple amplicons on 11q and 12q. There
are other examples in the literature of neuroblastoma
cell lines and tumors with very similar amplified regions
at 11q13 [11,25] or 12q13–q15 [11,21,30], respectively,
and in two tumors synchronous amplification on both
chromosomes have been reported [11,31,32], as in the
Cetinkaya et al. BMC Cancer 2013, 13:231 Page 12 of 14
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chromosome 11q13, and CDK4 and MDM2 on 12q13-
15 are interesting oncogenes in this context. Generally,
neuroblastomas with 11q13 amplicons were reported to
be clinically aggressive and associated with an older age
at diagnosis compared to children with MNA tumors of
the present study. However, those 11q13 amplified neu-
roblastomas which also displayed MNA were diagnosed
at earlier ages [11]. Clinical information on 12q ampli-
fied neuroblastoma is sparse in the literature but indi-
cates advanced disease [30,33,34]. MNA may occur also
in 12q amplified neuroblastoma [21,30,31]. Amplicons of
other chromosomal regions are described in single cases
of poor outcome neuroblastoma, involving 16q.21, 4q.33,
6p12-21 [25], 5q33.3 [11], and the MYC containing 8q24
region [26]. Hence, with the support of these previously
published data, it seems that our case harboring chromo-
some 11 and 12 amplifications is not totally unique and
implies that such and other non-MYCN amplifications
may underlie a minor subset of aggressive neuroblastomas.
Conclusions
On the basis of these categories, we suggest the follow-
ing metaphor for the genesis of unfavorable neuroblas-
toma: MNA, segmental deletion of 11q, and low-riskFigure 6 A proposed model for the age dependence of unfavorable neu
cellular origin of all neuroblastomas. Depending on genetic subtype the respe
effect - most evident when comparing MNA and 11q- tumors. As tumors with
adolescent presentation are poorly represented in the present study and in th
indicated by question marks. Abbreviation: NB: neuroblastoma; Symbols: Arrow
Arrow width/size of symbol for clinical disease: relative frequency of tumor subprecursor lesions provide an elevator, a staircase, and a
first step of a staircase, respectively, towards unfavorable
neuroblastoma. This metaphor builds on the notion that
the first steps in tumor development take place during
a common early developmental phase when the imma-
ture cells that are the source of neuroblastoma are still
present in the sympathetic nervous system, whereas sub-
sequent tumorigenic events differ in malignant effect be-
tween the genetic routes. Our speculations on main
routes for the pathogenesis of unfavourable neuroblas-
toma are summarized in Figure 6, showing the four
mentioned routes and adding also adolescent neuroblas-
toma as a separate, but still obscure, route. The present
delineation of genetic subsets of unfavorable neuroblas-
toma might have therapeutic implications. It would seem
that MNA tumors are more proliferative, which calls for
a dose-intensive treatment, and the relatively “clean” gen-
etics of MNA neuroblastomas would appear to make
them suitable for tailored treatments that target the func-
tions of MYCN, e.g. apoptosis [35]. Novel therapeutic
strategies specifically for 11q-deleted neuroblastoma are
urgently needed, and the identification of novel subsets of
neuroblastomas with non-MYCN amplifications may also
have therapeutic consequences, but these will have to
await more conclusive information on the genetic androblastoma. The model builds on the assumption of an early common
ctive tumorigenic hits differ in type, number and degree of malignant
alternative amplifications, putative low-to-high-risk progression, and
e literature these routes for tumor development are largely speculative,
s: tumorigenic hits; Darkness of arrow: degree of malignant transformation;
type; Solid curved blue line: low-risk neuroblastoma development.
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ity of a transition from low- to high-risk disease in some
cases may have implications for the monitoring of low-
risk rest tumors.
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Additional file 1: Figure S1. Schematic representation of genetic
profiles for neuroblastoma samples included in the study (n=34). Deleted
and gained regions are represented by red and green bars, respectively.
Cases are arranged according to genetic subgroup.
Additional file 2: Figure S2. Novel amplicons in association with MNA
on 2p: 32K whole-genome array data are shown from: (A) the primary tumor
of case ID55; (B) cell line U2715, which was established from this tumor.
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